DBV Technologies S.A. (DBVT) Cut to “Hold” at Zacks Investment Research
DBV Technologies S.A. (NASDAQ:DBVT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday.
According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
A number of other equities analysts also recently weighed in on the stock. Jefferies Group LLC reissued a “buy” rating on shares of DBV Technologies in a report on Thursday, August 31st. Leerink Swann boosted their price target on shares of DBV Technologies from $54.00 to $60.00 and gave the stock an “outperform” rating in a report on Friday, August 25th. BidaskClub raised shares of DBV Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, August 22nd. ValuEngine raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Finally, Morgan Stanley reissued an “overweight” rating on shares of DBV Technologies in a report on Monday, July 10th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $50.00.
DBV Technologies (DBVT) traded up 0.97% during mid-day trading on Friday, hitting $43.81. 125,679 shares of the stock were exchanged. The stock’s 50-day moving average is $44.13 and its 200 day moving average is $37.41. The company’s market capitalization is $2.02 billion. DBV Technologies has a 52 week low of $31.87 and a 52 week high of $46.33.
TRADEMARK VIOLATION NOTICE: This report was reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/09/08/dbv-technologies-s-a-dbvt-cut-to-hold-at-zacks-investment-research.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. purchased a new stake in DBV Technologies during the first quarter valued at about $1,120,000. Bank of America Corp DE lifted its holdings in DBV Technologies by 86.3% during the first quarter. Bank of America Corp DE now owns 26,574 shares of the company’s stock valued at $936,000 after purchasing an additional 12,309 shares during the last quarter. Morgan Stanley lifted its holdings in DBV Technologies by 89.9% during the first quarter. Morgan Stanley now owns 249,988 shares of the company’s stock valued at $8,805,000 after purchasing an additional 118,317 shares during the last quarter. Emory University lifted its holdings in DBV Technologies by 7.9% during the first quarter. Emory University now owns 62,884 shares of the company’s stock valued at $2,215,000 after purchasing an additional 4,628 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in DBV Technologies during the first quarter valued at about $853,000. 45.52% of the stock is currently owned by institutional investors and hedge funds.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.